Introduction

Multiple myeloma (MM) is a malignant neoplasm of clonal plasma cells, preceded in nearly all cases by an asymptomatic premalignant condition called monoclonal gammopathy of uncertain significance (MGUS). Incidence of MM is approximately 4/100,000/year, and MGUS occurs in 3–4% of individuals over 50 years of age, with an average rate of progression to MM of 0.5–1%/year. Patient outcomes have improved significantly over recent years. Kumar and colleagues showed a 50% improvement in overall survival in patients diagnosed after 1997 compared with those diagnosed before, with a clear role played by the advent of immunomodulatory drugs and proteasome inhibitors. Outcomes have likely improved further, and numerous additional therapeutic agents are now available.

The role of the immune system in myeloma is becoming increasingly understood. Therapies targeting the immunological components of myeloma genesis offer a means of continuing to improve disease outcomes while avoiding or further reducing dependence on traditional chemotherapeutics. Furthermore, evidence suggests that immune surveillance may play a critical role in the prevention of disease progression, therefore early use of immune-focused therapies may have the potential to halt progression altogether.

In this review, we discuss the current understanding of the effects on the immune system seen in MM and its premalignant stages, how these affect disease progression, and the therapies available or under development.

Dysfunctional immunity in myeloma

Within the bone marrow (BM), a complex interplay of interactions occurs between malignant plasma cells and normal BM components. In this section, we will describe myeloma’s immunosuppressive effects on various cell types and subsets, and how these facilitate immune evasion. These are summarized in Figure 1.

T-cells

T-cells form a crucial part of the adaptive immune system. They express unique antigen-specific T-cell receptors (TCRs), however they rely on antigen presentation by major histocompatibility

Abstract: Multiple myeloma (MM) has a worldwide incidence of 1–5/100,000/year. Outcomes have improved significantly in recent years following incorporation of immunomodulatory drugs and proteasome inhibitors into standard-of-care regimes. MM is profoundly immunosuppressive, enabling immune evasion, proliferation and disease progression. The role of the immune system in MM is becoming increasingly characterized and understood, and numerous therapies are under development or in routine clinical use targeting these elements of MM pathogenesis. In this review we discuss the immunosuppressive effects of MM, then the therapies targeting these defects. Specifically, we review the monoclonal and bispecific antibodies, alongside adoptive cellular therapies currently under investigation.

Keywords: antibodies, CAR T-cell, immunotherapy, myeloma

Received: 11 February 2019; revised manuscript accepted: 9 May 2019.
Figure 1. The major components of impaired immunity in myeloma:

- BMSC: bone marrow stromal cell
- MM: multiple myeloma
- NK: natural killer
- Treg: regulatory T-cell

BMSC: bone marrow stromal cell; MM: multiple myeloma; NK: natural killer; Treg: regulatory T-cell.
complex (MHC) class I (for CD8+ cells) or class II (CD4+ cells) molecules for activation.

Allogeneic stem cell transplantation (allo SCT) provided the initial evidence of the role of T-cells in myeloma. Graft-versus-host disease (GvHD), especially chronic disease, is associated with improved survival post-allo SCT, with a 5-year overall survival (OS) of 78.8% for those with chronic GvHD reported, compared with 42.6% without. The anti-tumour properties of donor lymphocyte infusions (DLIs) also correlate with the induction of GvHD and the quantity of lymphocyte dose.

Quantitative and qualitative T-cell changes are seen at varying stages of myeloma development. The peripheral blood CD4+/CD8+ T-cell ratio is reduced in MGUS and MM, and progresses with disease progression and increasing tumour burden, which have been shown to be independently associated with poor prognosis. Th1 cells are increased in both BM and peripheral blood compared with Th2 cells, and Th17 cells, a proinflammatory subset, are particularly prominent in BM samples. Tumour-specific clonal T-cell expansions may develop, more often with CD8+ than CD4+. Michalek and colleagues stimulated the development of tumour-specific T-cell clones in patients using dendritic cells (DCs) loaded with myeloma cell apoptotic bodies. These T-cells demonstrated cytotoxic effects against autologous tumour cells in vitro. Clonal CD8+ T-cell expansions are seen more frequently in patients with low tumour burdens, and T-cell populations from the BM of MGUS patients respond to autologous malignant cell exposure by vigorous cytokine production, which is not replicated using T-cells from myeloma patients, suggesting impaired functionality with disease progression. These studies cannot determine whether the impaired T-cell repertoire predisposes to disease progression or is caused by it, however experimental data suggest that immune surveillance may be involved in the prevention of progression. For example, T-cells specific for SOX-2, a gene critical for embryonic renewal of stem cells, were identified in around 25% of MGUS patients but absent in myeloma patients. Immunity to SOX-2 prevented the in vitro clonal growth of MGUS cells, suggesting that the loss of anti-SOX-2 immunity may facilitate the clonal escape of MGUS cells and disease progression.

T-cell dysfunction in myeloma is multifactorial. DCs, the central antigen-presenting cells (APCs), are impaired in MM. MM cells may induce T-cell anergy by presenting tumour-specific antigens without co-receptor expression. Brown and colleagues showed reduced expression of the B7-1 (CD80) costimulatory molecule on MM cells alongside downregulation of its counter receptor molecule CD28 on expanded T-cell clones, leading to T-cell anergy. These tumour cells still express CD86 (B7-2) which interacts with cytotoxic T-lymphocyte associated antigen-4 (CTLA-4), noted to be upregulated in the T-cells. CTL4 binding dampens effector T-cell activation and regulates immune homeostasis. Interactions between programme cell death receptor-1 (PD-1) and its ligand (PD-L1) are another mechanism of immune suppression. PD-L1 is expressed by various nonlymphoid cells and tumour cells. PD-1/PD-L1 binding suppresses the activation and proliferation of autoreactive T-cells, inducing T-cell exhaustion, reduced cytokine production and impaired cell lysis. PD-L1 also binds to B7-1, mediating T-cell inhibition. Increased levels of PD-L1 in myeloma cells alongside T-cell exhaustion has been demonstrated, and PD-L1 blockade in mice was shown to improve survival post-stem cell transplant and whole-cell vaccination. TIGIT (T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain) is another inhibitory immune receptor expressed on T-cells and natural killer (NK) cells. Increased TIGIT expression on T-cells has been noted in patients with MM during disease progression. These T-cells exhibited a dysfunctional phenotype and demonstrated impaired proliferation and cytokine production. Addition of a monoclonal antibody against TIGIT led to improved T-cell function and suppressed MM development. Studies focused on specific T-cell subsets have provided further information. Regulatory T-cells (Tregs) are immunosuppressive and required for normal immune homeostasis. CD4(+)CD25(+)FoxP3(+) Tregs are elevated in the peripheral blood of myeloma patients, with levels correlating with disease burden, and also seen in MGUS, suggesting a possible role in early myeloma genesis. Furthermore, myeloma cells have been shown to induce the formation of immunosuppressive Tregs in vitro. NK T-cells express both TCRs and NK cell surface markers,
recognizing antigens via CD1d molecules. Invariant NK T-cells (iNKTs) involved in tumour immunosurveillance, have been shown to be functionally impaired in myeloma patients with a reduced ability to produce interferon gamma (IFN-γ), possibly relating to the loss of CD1d expression by MM cells. Stimulation of iNKT cells by the α-galactosyl ceramide ligand can produce strong anti-tumour responses against MM cells in vivo.15

NK cells

NK cells are a critical component of the innate immune system, and unlike T-cells, do not require antigen exposure to mount a response. Their effector function is determined by a balance between signals produced by inhibitory and activating receptors recognizing their respective ligands on tumour cells, or virally infected cells. Disruption of this balance enables immune evasion.

The most well characterized inhibitory receptors are the killer immunoglobulin-like receptor (KIR) superfamily, recognizing MHC (polypeptide related sequence) Class I antigens. Others include CD94/NKG2A (CD159a), ILT2, PD-1 and TIGIT. Activating receptors include NKG2D (CD314), which recognizes the MHC-related ligands MICA and MICB, the natural cytotoxicity receptors (NCRs), CD94/NKG2C (CD159c), CD16 (FcγRIIIA), the SLAM-related 2B4 (CD244) receptor, and DNAM-1 (CD226), which is regulated by TIGIT and CD96 (TACTILE).16 Low-dose bortezomib was shown to increase expression of NKG2D and DNAM-1 ligands on myeloma cell lines, sensitising the cells to NK-mediated lysis,17 suggesting a possible synergism between proteasome inhibition and NK cell therapies.

One of the most important inhibitory signals is HLA-E, which suppresses NK and T-cell activity through its interaction with NKG2A. Genetic variation in HLA genes means that around 40% express high levels of HLA-E and 60% express low levels. The impact of HLA-E expression was assessed in the MM Research Foundation CoMMpass study. Patients with high HLA-E expression were found to have a significantly shorter duration of progression-free survival (PFS) than those with medium or low-level expression. Mass cytometry in these patients also identified expansions of immune-suppressive T-cells with high levels of PD-1 and TIGIT expression, as well as a subset of Tregs, which were not seen in the groups with medium or low-level HLA-E expression.18

MM cells and Tregs produce high levels of transforming growth factor (TGF)-β, which downregulates NK-activating receptors and impairs NK cytotoxicity. Elevated interleukin (IL)-10 levels inhibit IFN-γ and tumour necrosis factor (TNF)-α production, elevated IL-6, produced by both MM and bone marrow stromal cells (BMSCs) may inhibit NK activity, and elevated BM prostaglandin E2 levels inhibit activating signals via NCR, NKG2D and CD16.16 Additionally, myeloid-derived suppressor cells (MDSCs) downregulate NK activity via the Nkp30-activating receptor, membrane-bound TGF-β and TIGIT-mediated signalling.16,19,20

Presence of stress-induced MICA/B ligands on tumour cells activates NK cytotoxicity via NKG2D. Metalloproteinase-mediated cleavage of MIC generates soluble MIC ligands (sMICs). These cause internalization of NKG2D and other NK-activating receptors, leading to impaired cytotoxic activity.21 MIC shedding has been seen in myeloma following exposure to doxorubicin and melphalan chemotherapy.22 Surface plasma cell MICA expression is known to decrease with progression from MGUS to MM,23 alongside other activating ligands. Conversely, there is evidence for upregulation of inhibitory ligands, for example, HLA Class I antigens.24 In fact, MM cells from advanced disease states are so immunosuppressive to NK cells that they can evade killing by NK cells from normal healthy donors.25

A further immune-evasive mechanism utilised by myeloma cells is surface expression of sialylated glycans, which bind to Siglecs (sialic acid-binding lectin receptor)-7 on NK cells (and Siglecs-9 on macrophages). Both treatment of MM cells with a sialytransferase inhibitor and use of NK cells lines with low Siglecs-7 expression, produces a significant increase in NK-mediated cell death.26

Finally, NK cells in MM may show an exhausted phenotype, with downregulation of activating receptors, for example, NKG2D, Nkp46 and DNAM-127 and increased expression of PD-1, leading to disrupted cytotoxicity and cytokine
production, and further increasing the ability of the malignant cells to escape immune surveillance.

**Dendritic cells**

DCs are professional APCs forming a critical link between the innate and adaptive immune system. High levels of circulating IL-6 in MM impairs the generation and function of DCs, stimulating CD34+ cells to differentiate into monocytic cells with potent phagocytic ability but no antigen-presentation activity. DCs isolated from MM patients have been shown to be unable to present tumour epitopes, unlike DCs from donors or those generated in vitro from CD14+ patient monocytes without exposure to excess IL-6. Use of an IL-6 receptor alpha-chain knockdown DC vaccine in a murine model lead to increased production of tumour-specific CD8+ T-cells, increased cytokine production and improved PFS.

Hypersialylation of MM cells may additionally impair DC functioning, via binding to Siglec-7/9 receptors on the DCs, leading to blunted T-cell activation, which can be ameliorated by inhibiting sialic acid expression.

**Macrophages**

Tumour-associated macrophages (TAMs) are derived by recruitment and activation of circulating monocytes by cytokines and chemokines produced by tumour cells and BMSCs. Activated macrophages are polarized into M1 or M2 macrophages. M1 macrophages are proinflammatory and produce high levels of TNF-α and IL-12, often in response to infections. TAMs usually resemble M2 macrophages, which are immunosuppressive, for example through expression of PD-L1, and stimulate angiogenesis favouring tumour growth. Myeloma cells produce chemokines, for example, PGE2 which may attract and polarize macrophages to the M2 phenotype. IL-12, produced by M1 macrophages can downregulate myeloma cell angiogenesis and impair tumour growth. Moreover, predominance of M2 macrophages has been linked to resistance to daratumumab/immunomodulatory drug (IMiD) combinations. Strategies to
repolarize macrophages could aid restoring responsiveness to daratumumab and other monoclonal antibodies.

**MDSCs**

This heterogenous group of cells is characterized by myeloid origin, immaturity and potent suppression of T-cell responses. MDSCs rapidly expand in response to infection, inflammation and malignancy, preventing massive T-cell over-activation and cytokine release.35 This occurs partly by upregulation of inducible nitric oxide synthase (iNOS), leading to increased nitration of tyrosine residues in T-cells, preventing phosphorylation and inhibiting T-cell function. These cells are present at five-times normal levels in patients with newly diagnosed myeloma, providing yet another means of tumour escape from immune surveillance. Phosphodiesterase-5 (PDE-5) inhibitors, (e.g. sildenafil or tadalafil) downregulate iNOS production and can inhibit the suppressive effect of MDSCs on T-cell immunity.36

**Therapeutics**

Many of the agents used as standard of care in MM, alongside the novel targeted therapies have an immunomodulatory component to their mechanism of action. Here we will discuss the various classes of agents in turn, with a particular focus on the monoclonal and bispecific antibodies and cellular therapies under development. These are summarized in Figures 2 and 3, and key clinical trials in Table 1.

**BM stromal cells and adipocytes**

BMSCs produce numerous cytokines and chemokines responsible for regulation of plasma cell migration, homing to the bone marrow niche, proliferation and survival, for example, CXCL-12 which binds plasma cell CXCR4 and facilitates migration, alongside IL-6, VCAM and CD44.37 Elevated IL-6 is a poor prognostic feature, and high levels of the soluble IL-6 receptor correlate with poor responses to chemotherapy.38 As mentioned previously, IL-6 has implications for T-cell, NK cell and DC immunity, and blocking IL-6 has been shown to improve tumour-specific responses in a murine model.30

**Immunomodulatory drugs**

The IMiDs are thalidomide and its derivatives lenalidomide and pomalidomide. In *vitro* exposure
Table 1. Clinical studies of myeloma immunotherapies.

| Trial ID | Intervention | Target | Patients | Outcomes |
|----------|--------------|--------|----------|----------|
| **Checkpoint inhibitors** | | | | |
| NCT02289222<sup>39</sup> | Pembrolizumab with pomalidomide and dexamethasone | PD-1 | 48 patients with RRMM with prior exposure to an IMiD and PI | ORR 60%, VGPR 19%, CR 8% PFS 17.4 mon |
| KEYNOTE-185 NCT02579863<sup>40</sup> | Pembrolizumab with lenalidomide and dexamethasone versus len/dex | PD-1 | 301 NDMM, transplant-ineligible patients enrolled (640 planned) | Trial halted after interim analysis on the first 301 patients. 19 (13%) of patients in the pembro/len/dex arm died- 6 from PD, 13 from AEs versus 9 (6%) in the len/dex arm |
| KEYNOTE-186 NCT02576977<sup>41</sup> | Pembrolizumab with pomalidomide and dexamethasone versus pom/dex | PD-1 | 249 RRMM patients enrolled (300 planned) | Trial halted after in-term analysis on the first 249 patients. Median PFS 5.6 mon versus 8.4 months in the pom/dex arm. 29 (23%) versus 21 (17%) died in the intervention arm. Risk–benefit profile was felt to be unfavourable |
| **Monoclonal antibodies** | | | | |
| SIRIUS NCT01985126<sup>42</sup> versus | Single-agent daratumumab | CD38 | 106 patients with RRMM who had received ≥3 prior therapies including and IMiD and PI received 16 mg/kg of dara | ORR 29%, VGPR or better 12.2% 12-month OS 65%, median OS 17.5 mon, median PFS 3.7 mon Fatigue (40%) and anaemia (33%) were the most common AEs |
| POLLUX NCT02076009<sup>43</sup> | Daratumumab with lenalidomide and dexamethasone versus len/dex | CD38 | 569 RRMM transplant-eligible patients with ≥1 treatment | 12-month PFS 83.2% in the dara arm versus 60.1% At median follow up of 13.5 mon, HR for death or disease progression was 0.37 for daratumumab-treated patients versus control arm. ORR 93% versus 76%, CR 43% versus 19%, 22% MRD negative in the dara arm versus 5% with len/dex Increased neutropenia in the dara arm (52% versus 37% grade 3–4), IRRs in 48%, mostly grade 1–2 |
| CASTOR NCT02136134<sup>44</sup> | Daratumumab with bortezomib and dexamethasone versus bort/dex | CD38 | 498 RRMM transplant-eligible patients | 12-month PFS 60.7% in the dara arm versus 26.9%, ORR 83% versus 63%, VGPR of better 59% versus 29%, CR or better 19% versus 9% Increased thrombocytopenia (45% versus 33%) and neutropenia (41% versus 4%) in the dara arm, IRRs in 45%, grade 3 in 8.6% only |

(Continued)
| Trial ID       | Intervention                                                                 | Target      | Patients                                      | Outcomes                                                                                                                                 |
|---------------|-------------------------------------------------------------------------------|-------------|-----------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------|
| ELOQUENT-2    | Elotuzumab with lenalidomide and dexamethasone versus len/dex                 | SLAMF7      | 646 patients with RRMM having had 1–3 prior therapies | ORR 79% with elo/len/dex versus 66% with len/dex 3-year PFS 26% versus 18%, median OS 43.7 versus 39.6 mon Grade 3–4 AEs occurred in 78% on elo/len/dex versus 67% on len/dex. AEs more frequent with elo/len/dex were fatigue [48% versus 40%], diarrhoea [48% versus 37%], constipation [33% versus 19%] and cough [33% versus 19%] |
| NCT02514239   | AMG-420 (previously BI 836909)                                                | BCMA        | 35 patients with RRMM and ≥2 prior therapies received AGM-420 0.2–800 µg/d | 6 CRs MRD negativity achieved in all patients receiving 400 µg/d CRS in 3 patients [grade 3 in 1]. MTD 400 µg/d |
| BMA117159     | GSK285916 Anti-BCMA antibody linked to antimitotic monomethyl auristatin F    | Anti-BCMA   | 35 patients with RRMM with prior exposure to IMiDs, PIs and alkylators received 3.4 mg/kg GSK285916 | ORR 60%, CR or sCR 15%, VGPR 40% PFS 12 mon, median duration of response 14.3 mon Most common AEs were thrombocytopenia [63%], blurred vision [51%] and cough [40%]. Most common SAEs were pneumonia/lung infection [15%] and IRRs [6%] |
| NCT00566098   | Autologous Marrow infiltrating lymphocytes post-salvage ASCT                  | Tumour-specific MILs | 25 patients with NDMM or RRMM undergoing ASCT | CR 27%, PR 27%, SD 23% PFS was significantly longer in those achieving a 90% reduction in disease burden [25.1 mon versus 11.8 mon] |
| NCT01352286   | NY-ESO-1/LAG-1 T-cells post-ASCT                                              | NY-ESO-1 and LAGE-1 | 20 patients with antigen-positive myeloma received an average $2.4 \times 10^9$ engineered T-cells | ORR 80% Median PFS 19.1 mon, OS 32.1 mon 7 SAEs and 17 AEs occurred, no significant CRS, 3 patients developed biopsy confirmed acute GvHD |
| NCT02135406   | CD19 CAR T-cells post-salvage ASCT                                            | CD19        | 10 patients with RRMM who had progressed within 1 year of ASCT | ORR 80% Median PFS 185 days 100% have since progressed 1 case of grade 3 GvHD, 1 grade 1 CRS |
| Trial ID | Intervention | Target | Patients | Outcomes |
|----------|--------------|--------|----------|----------|
| SZ-CART-MM02 | CD19 and BCMA-CAR T-cells post-fatigue ASCT | CD19 and BCMA | 10 patients with high-risk MM eligible for tandem ASCT | At >90 days, VGPR or better in 100% of the 9 patients who have completed therapy, stringent CR in 51% MRD negativity seen in 37.5% post-ASCT and 66.7% post-CAR T-cell CRS occurred in 100% (grade 1-2) |
| NCT02215967 | Anti-BCMA-CAR T-cells post-fludarabine and cyclophosphamide | BCMA (anti-BCMA scFv and CD28 costimulatory domain) | 12 patients with RRMM Received 4 different levels of CAR-Ts (0.3 × 10⁶ cells/kg, 1 × 10⁶ cells/kg, 3 × 10⁶ cells/kg, and 9 × 10⁶ cells/kg) | 10 patients received the lower 3 doses, at the lowest 2 doses, limited anti-MM activity was seen. 1 patient in the third dose level achieved VGPR. Of the 2 patients receiving the highest level one achieved sCR for 17 weeks and the other a VGPR for 66 weeks, both had CRS and prolonged cytopenias |
| CRB-401 | Bb2121 CAR T-cells post-fludarabine conditioning | BCMA (4-1BB costim domain and same scFv as 53) | 18 RRMM patients who have been treated with daratumumab received ≥150 × 10⁶ CAR T-cells 21 patients were treated in total in 4 dose-escalation cohorts | Of patients receiving ≥150 × 10⁶ cells, ORR 94%, CR 56% PFS 81% at 6 mon, 71% at 9 mon, median not reached Of all patients, CRS (mainly grade 1–2) occurred in 71% (grade 3 in 2 patients), 2 patients died |
| CRB-402 | Bb2121 CAR T-cells | BCMA (bb2121 treated with PI3K inhibitor bb007) | 12 patients with RRMM Responses in 6/7 evaluable patients, ORR 83%, VGPR or better 75%, CR/sCR 25%, MRD negative in 3/3 responses tested CRS in 67%, grade 3 in 1 patient, neurotoxicity in 25% |
| LEGEND-2 | LCAR-B38M CAR T-cells post cyclophosphamide infusion | BCMA (2 epitopes targeted) | 19 patients with RRMM received a median of 4.7 × 10⁶ cells/kg | ORR 100% at median 17 months follow up, 95% reached CR or near CR in 6 months follow up. CRS occurred in 74% (1 grade 3 and 1 grade 4) |
| LEGEND-2 | LCAR-B38M CAR T-cells post cyclophosphamide infusion | BCMA (2 epitopes targeted) | 57 patients with RRMM | ORR 88%, CR 68%, MRD negative in 63% Median PFS 15 mon at median 8 mon follow up 90% CRS, 7% ≥grade 3 |
| Trial ID       | Intervention                                                                 | Target                      | Patients                                                                 | Outcomes                                                                                      |
|---------------|-----------------------------------------------------------------------------|-----------------------------|--------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------|
| NCT02481934   | NK cell infusions with lenalidomide or bortezomib-based regimens            | KIR-HLA mismatch            | 5 RRMM patients with 2–5 prior lines of therapy received 4 cycles with 2 infusions of $7.5 \times 10^6$ cells/kg/cycle | SD in 4/5 patients with 1 response maintained after 1 year Neutropenia grade 2 occurred in 2 patients related to chemotherapy |
|               |                                                                             |                             |                                                                         |                                                                                               |
| NCT01729091   | Cord-derived NK cells with lenalidomide and ASCT                            | KIR-HLA mismatch            | 33 patients eligible for ASCT received lenalidomide D-8 to -2, melphelan D-7, NKs D-5 and stem cell return D0 | Responses at 3 months- CR 55%, VGPR 12%, PR 21% With a median follow up of 22 mon 10 have progressed and 3 died No toxicities were reported |
|               |                                                                             |                             |                                                                         |                                                                                               |
| Vaccines      |                                                                             |                             |                                                                         |                                                                                               |
| NCT00458653   | Dendritic-tumour fusion vaccine administered post-ASCT following haematopoietic recovery | Tumour epitopes             | 24 patients received serial vaccinations following ASCT, 12 patients received pre- and post-ASCT vaccination | SD in 70% for at least 2 months 24% of patients who achieved PR following ASCT converted to CR/ nCR after vaccination |

AE, adverse event; ASCT, autologous stem cell transplant; BCMA, B-cell maturation antigen; BiTE, bispecific T-cell engager; bort, bortezomib; CR, complete response; CRS, cytokine release syndrome; dara, daratumumab; dex, dexamethasone; elo, elotuzumab; GvHD, graft-versus-host disease; HR, hazard ratio; IMiD, immunomodulatory drug; IRR, infusion-related reaction; KIR, killer immunoglobulin-like receptor; len, lenalidomide; MIL, marrow infiltrating lymphocyte; MM, multiple myeloma; mon, months; MRD, minimal residual disease; MTD, maximum tolerated dose; nCR, near complete response; NCT, ClinicalTrials.gov identifier; NDMM, newly diagnosed multiple myeloma; NK, natural killer; ORR, overall response rate; OS, overall survival; PD, progressive disease; PD-1, programmed cell death receptor 1; pembro, pembrolizumab; PFS, progression free survival; PI, proteasome inhibitor; PR, partial response; RRMM, relapsed refractory MM; SAE, serious adverse event; sCR, stringent complete response; SD, stable disease; TCR, T-cell receptor; VGPR, very good partial response.
of stem cells to IMiDs leads to growth and activation of DCs in a mouse model.⁶¹ Lenalidomide and pomalidomide have been shown to enhance tumour antigen uptake and presentation by DCs, inhibit Tregs, and increase IL-2 and IFN-γ production, all leading to improved T-cell responses.⁶²,⁶³ IMiDs act via binding to cereblon, a component of the Ikaros family zing finger protein transcription factors 1 and 3, and reduced transcription of MYC and IRF4, required for survival and proliferation.⁶⁴ Reduced levels of IKZF1/3 result in the upregulation of IL-2 and IFN-γ, stimulating NK growth and activity. A study using IL-2-primed peripheral blood mononuclear cells treated with thalidomide demonstrated significantly increased lysis of MM cell lines, independent of MHC class, and inhibited by depletion of CD56 positive cells, strongly suggesting NK-mediated killing.⁶⁵

**Checkpoint inhibitors**

PD-L1 is highly expressed on MM cells, as well as certain immune-suppressive cells within the tumour microenvironment (TME). Presence of PD-L1 impairs both T-cell and NK cell immunity, and levels of soluble PD-L1 have been shown to be independently associated with worse outcomes following upfront treatment.⁶⁶ A phase II study of 48 patients combined the PD-1 antagonist pembrolizumab with pomalidomide and dexamethasone in patients with RRMM (relapsed refractory MM), reporting 60% overall response rate (ORR), 19% very good partial response (VGPR) and 8% complete response (CR).⁶⁹ Studies of nivolumab, as a single agent however, failed to show efficacy.⁶⁷ Lenalidomide reduces the expression of both PD-L1 by myeloma cells and dexamethasone in patients with RRMM.⁶⁸ The addition of lenalidomide has been shown to improve the ADCC of daratumumab in preclinical studies, and in our experience, low doses of cyclophosphamide augment macrophage-dependent ADCP, which will be discussed further under the heading of cyclophosphamide.⁶⁹,⁷⁰ Phase III trials of daratumumab with either lenalidomide/dexamethasone (POLLUX) or bortezomib/dexamethasone (CASTOR) in transplant-eligible patients have shown impressive responses in RRMM with a 12-month PFS of 83.2% versus 60.1% for standard of care, and 60.7% versus 26.9% respectively.⁴³,⁴⁴ Nontransplant candidates also have excellent responses with upfront daratumumab, in combination with bortezomib/melphalan/prednisolone in the ALCYONE trial, and lenalidomide/dexamethasone in the MAIA trial, presented as a late breaking abstract at ASH 2018.⁴¹,⁷¹ Based on the ALCYONE data, daratumumab is licensed upfront in elderly patients in Europe.

Elotuzumab is a humanized anti-CD38 monoclonal antibody that kills myeloma cells through antibody-dependent cellular cytotoxicity (ADCC), which relies upon binding of NK cell CD16 (FcγRIIIA), complement-dependent cytotoxicity (CDC) and antibody-dependent cellular phagocytosis (ADCP). Single-agent daratumumab yielded an ORR of 29% in RRMM.⁴² The addition of lenalidomide has been shown to improve the ADCC of daratumumab in preclinical studies, and in our experience, low doses of cyclophosphamide augment macrophage-dependent ADCP, which will be discussed further under the heading of cyclophosphamide.⁶⁹,⁷⁰ Phase III trials of daratumumab with either lenalidomide/dexamethasone (POLLUX) or bortezomib/dexamethasone (CASTOR) in transplant-eligible patients have shown impressive responses in RRMM with a 12-month PFS of 83.2% versus 60.1% for standard of care, and 60.7% versus 26.9% respectively.⁴³,⁴⁴ Nontransplant candidates also have excellent responses with upfront daratumumab, in combination with bortezomib/melphalan/prednisolone in the ALCYONE trial, and lenalidomide/dexamethasone in the MAIA trial, presented as a late breaking abstract at ASH 2018.⁴¹,⁷¹ Based on the ALCYONE data, daratumumab is licensed upfront in elderly patients in Europe.

Elotuzumab is a humanized anti-SLAMF7 (signalling-lymphocyte-activating molecule F7) monoclonal antibody, also reliant upon NK-mediated ADCC and macrophage-mediated ADCP. Single-agent elotuzumab has not demonstrated significant efficacy; however, responses have been seen
in combination with IMiDs or proteasome inhibitors, for example, the ELOQUENT-2 study with lenalidomide/dexamethasone reported a 27% reduction in risk of death or disease progression at 3 years in the elotuzumab arm.45

Evidence of progressive NK cell impairment with disease progression suggests that these agents might be more efficacious upfront. Efforts to ameliorate the NK defects present in MM are described in a later section.

**Bispecific T-cell engagers, bispecific antibodies and bispecific engagers**

Bispecific antibodies offer several potential advantages over monospecific antibodies. They can simultaneously inhibit multiple survival and proliferation pathways or redirect immune cells to the tumour through expression of T-cell/NK-cell activating receptors, or increase tumour specificity via expression of more than one tumour-specific antigen, thereby reducing off-target toxicity.

Bispecific antibodies are classified as immunoglobulin (Ig)G-like, and non-IgG-like molecules, by the presence or absence of an Fc region. IgG-like bispecifics are capable of Fc-mediated functions, that is, ADCC, ADCP or CDC. They are larger, more stable with a longer half-life. Bispecific T-cell engagers (BiTEs) are a form of non-IgG-bispecific antibody, an scFv-based antibody, comprising only the variable heavy and light chain regions. They are smaller with improved tumour specificity and tissue penetration, but a shorter half-life necessitating frequent administration or continuous infusion.72

BiTEs target a tumour epitope and a T-cell antigen, usually CD3. Recognition of the tumour epitope leads to T-cell engagement, activation, and cytotoxicity directed against the tumour cell, independent of TCR specificity, MHC complex expression, and antigen presentation. A phase I trial of the CD19-CD3 BiTE, blinatumomab in combination with salvage autologous stem cell transplant (ASCT) is due for completion in 2019 (ClinicalTrials.gov identifier: NCT 03173430). MM cells typically do not express CD19, however various groups have isolated CD19-positive cells resembling B-lymphocytes, which give rise to MM cell colonies in vitro, and may act as myeloma stem cells,73,74 hence the rationale for blinatumomab use.

BCMA (B-cell maturation antigen) has been the focus of the majority of BiTEs to date.75–77 BCMA is a member of the TNF-receptor superfamily required for differentiation of B-cells into plasma cells. The BI 836909 BiTE,76 showed promising in vitro data and was acquired by AMGEN as AMG-420. Early phase I results are encouraging: Of 35 patients, 6 CRs have been achieved, with minimal residual disease (MRD) negativity in all patients receiving a dose of 400 µg/d. Serious adverse events (SAEs) occurred in 49%, with infection the most common at 29%. There were three patients (9%) who developed cytokine release syndrome (CRS), which was grade 3 in one patient and grade 1 in the other two patients.46 Another AMGEN BCMA BiTE under development is AMG-701, similar to AMG-420, but with an extended half-life.78

Other bispecific antibodies under investigation include the tetravalent NK-engager AFM26, which targets MM BCMA and CD16a on NK cells to induce NK-mediated cell killing.79 The requirement of CD16a for effective ADCC is hampered in approximately 80% of patients by the presence of a low affinity CD16a polymorphism. AFM26 interacts with NK cells with high-avidity, irrespective of this polymorphism.80 An anti-CD16a/BCMA/CD200 antibody further increases specificity to tumour cells by binding both BCMA and CD200 on MM cells.81

**Antibody–drug conjugates**

Antibody–drug conjugates are also in trial stages. GSK285916 is an anti-BCMA antibody linked to the antimitotic agent monomethyl auristatin F. In a phase I study of GSK285916 monotherapy in 35 patients with RRMM, ORR was 60% with CR or stringent complete response (sCR) in 14%, PFS was 12 months and median duration of response of 14.3 months. The most common adverse events (AEs) reported were thrombocytopenia (63% overall, 35% grade 3–4), blurred vision (51%, 3% grade 3, no grade 4 events), which was due to the effect of the monomethyl auristatin F, and cough (40%, grade 1–2 only). The most common SAEs were pneumonia or lung infection (15%) and infusion-related reactions (6%). Overall, 11% had AEs leading to trial discontinuation and 66% required dose-reductions.47,48,82 Both the US FDA and European Medicines Agency have since granted breakthrough status and PRIME designation respectively.
Cyclophosphamide
While cyclophosphamide is known to be an alkylator, it also has additional, valuable, immune-modulatory properties, which may enhance the activity of other immune based therapies. Metronomic dosing of cyclophosphamide selectively reduces Tregs, allowing expansion of effector T-cells and enhanced NK activation, and may repolarize macrophages from the M2 to M1 phenotype.

The anti-CD38 monoclonal antibody daratumumab acts through ADCC and macrophage-dependent ADCP. In our experience, cyclophosphamide augments daratumumab-induced ADCP, possibly via upregulation of Fc receptor gamma 1 (CD64) and reduction in CD47 (a ‘don’t eat me’ antigen) expression by tumour cells. This was confirmed by work in which macrophages were conditioned using culture media from myeloma cells exposed to low-dose cyclophosphamide, then incubated with MM cells and daratumumab. Enhanced daratumumab-induced ADCP of MM cells was demonstrated, alongside reduced MM CD47 expression.

Cellular therapies
The first cellular therapies took the form of allo SCT and DLIs. Chronic GvHD confers protection against relapse, and DLIs can induce a graft-versus-tumour effect. However, the increased rate of CR associated with allo SCT is offset by a high transplant-related mortality, partly attributable to GvHD. These data have prompted investigators to develop autologous T-cell therapies, aiming to preserve the anti-tumour effect but reduce or eliminate GvHD.

Adoptive T-cell therapies. Autologous T-cells are extracted from peripheral blood or BM (marrow infiltrating lymphocytes; MILs), then primed by antigenic stimuli, or genetically altered. The lymphocytes are expanded in vitro, usually by CD3/CD28 ligation, then reinfused into the patient.

Nonengineered. Studies of nonengineered T-cells have not demonstrated significant utility. MILs offer a theoretical advantage as their exposure to MM cells in the BM is increased, and tumour-specific populations are likely to be more prevalent. MILs also express the adhesion molecule CXCR4, to improve homing to the marrow. A trial of MILs post-salvage ASCT in RRMM reported 27% CR, 27% partial response (PR) and 23% stable disease, although the proportion of response attributable to the MILs versus ASCT is uncertain. Phase II trials are ongoing.

Engineered. Engineering a T-cell population enables delivery of far larger doses of tumour-specific T-cells. Autologous T-cells are transfected in vitro with viral vectors carrying the gene of interest, either a TCR, or a chimeric antigen receptor (CAR).

TCR T-cells. T-cells are engineered to encode TCRs against specific tumour antigen peptide-MHC complexes. One study using NY-ESO-1/LAG-1 TCR T cells in 20 patients reported responses in 80%, median PFS of 19.1 months and OS of 32.1 months. A total of 7 SAEs occurred (cytopenias, hypotension, hyponatraemia and GvHD) all of which resolved. Overall, three patients had diarrhoeal illnesses due to confirmed gastrointestinal GvHD. TCR T-cells require the presence of certain HLA antigens and can be circumvented by tumour MHC-downregulation. They have been largely superseded by CART-cells.

CAR T-cells. CAR T-cells are engineered TCRs with an extracellular domain comprised of a single chain variable fragment of a tumour-specific monoclonal antibody. CAR T-cells can recognize a specific tumour epitope in the absence of MHC presentation and are independent of HLA type. In first generation CART-cells a transmembrane domain connects the antigen-recognition domain to the T-cell-activating CD3-zeta domain. Binding of the tumour epitope by the CAR therefore causes direct cytotoxic T-cell activation.

These first generation CAR T-cells were able to elicit a weak, short-lived T-cell response. Second and third generation CAR T-cells have an additional one or two, respectively, costimulatory domains (usually CD28 or 4-1BBB) which enhance cytokine production and cytolytic capacity. The major toxicity of CAR T-cell therapy is CRS, due to the potent T-cell response generating a burst of IL-6, IFN-γ and other cytokines. This can cause hypotension, hypoxia, neurological dysfunction, multiorgan failure and fatality. Tocilizumab, an anti-IL6 receptor antagonist, and supportive care form the mainstay of management.
CD19 CAR T-cells are US FDA-approved for use in relapsed refractory B-cell precursor-ALL and non-Hodgkin lymphoma. Use in MM was trailed in order to target postulated CD19-positive myeloma stem cells. A total of 10 patients received salvage ASCT and CD19 CAR T-cells. ORR was 80% but all the patients progressed with a median PFS of 185 days.51 A study using 10 times the dose of CD19 CAR T-cells post front-line ASCT is ongoing (ClinicalTrials.gov identifier: NCT02794246), and another using CD19 and BCMA-CAR T-cells post-ASCT has reported an ORR of 100% in nine evaluable patients, with increased MRD negativity post-CAR T-cell infusion (37.5% post-ASCT to 66.7% post-CAR T-cells).89

Other antigen targets have been trialled in myeloma with varying degrees of success. CD44v6, CD70, CD38, CD138, kappa light chain, SLAMF7, and GPRC5D (G protein-coupled receptor class C group 5 member D)90 are examples. The challenge of target selection is identifying an epitope which is present in high concentration on MM cells in a significant proportion of myeloma patients, but not present on normal haematopoietic cells or other tissues. Very few epitopes meet these criteria. CD38 for examples, is present on malignant and benign plasma cells, T-cells, B-cells, NK cells, DCs, erythrocytes and many others. Targeting such antigens leads to ‘on target/off tumour’ effects. Drent and colleagues optimized the affinity of their CD38-CAR T-cells to bind to strongly CD38-positive myeloma cells, but to have inadequate affinity to bind to cells with lower levels of expression. This produces T-cell-mediated MM cell lysis with the sparing of normal haematopoietic cells.91

The most promising work has been using anti-BCMA-CAR T-cells. BCMA is expressed by late memory B-cells, plasmablasts, mature plasma cells and myeloma cells, but not haematopoietic stem cells or nonhaematopoietic cells.92 The first-in-human clinical trial of anti-BCMA-CAR T-cells, run by the National Cancer Institute (NCI), used fludarabine/cyclophosphamide followed by a CAR T-cell infusion in 12 patients with RRMM. Of these, 10 received a low dose, obtaining mostly stable disease. Of the two patients receiving the higher dose, one achieved stringent CR for 17 weeks and the other, VGPR for 66 weeks, but both had severe CRS.53 Bluebird Bio received breakthrough status by the US FDA for the bb2121 BCMA-CAR. 21 patients with RRMM, two thirds with adverse cytogenetics, were infused with bb2121, an anti-BCMA-CAR expressing the same single chain Fc portion as the NCI trial used, but with a 4-1BB costimulatory domain. The latest results were presented at ASCO 2018. At doses of $\geq 150 \times 10^6$ the ORR was 94% with a CR of 56%. Overall, 71% of patients had CRS which was generally mild, and only one fifth required tocilizumab. Median PFS has not yet been reached. Rates at 6 and 9 months are 81% and 71% respectively, and a deepening of response over time has been noted, with several patients converting to CR from initial VGPR.54 A modification of the bb2121 CAR, termed bb21217, is treated with the phosphoinositide-3 kinase inhibitor bb007 during ex vivo culture. This enriches the product for memory-like T-cells, leading to increased persistence and efficacy of the CAR T-cell product. Early results have shown responses in six out of seven evaluable patients, with MRD negativity demonstrated in all of the three responses tested.55

Legend Biotech’s LCAR-B38M anti-BCMA-CAR has two different heavy chain variable domains which recognize separate epitopes of the BCMA antigen. Initial data showed an ORR of 100% at a median 17 months follow up in 19 evaluable patients.56 The LEGEND-2 trial (ClinicalTrials.gov identifier: NCT03090659) recently reported results on 57 patients who received LCAR-B38M CAR T-cells. Grade 3 AEs occurred in 65%, with leukopenia (30%) and thrombocytopenia (23%) most commonly reported. CRS occurred in 90% but the majority of cases were grade 1–2 (83%). ORR was 88% with a CR of 68% and 63% of patients achieving MRD negativity. At a median follow up of 8 months, median PFS was 15 months.57

Finally, preclinical studies are trying to overcome the challenge of heterogenous BCMA expression and antigen escape which limit effectiveness of current BCMA targeted therapies. APRIL (A proliferation-inducing ligand), a member of the TNF superfamily of ligands, binds simultaneously to both BCMA and TACI (transmembrane activator and calcium modulator and cyclophilin interactor), both of which are consistently upregulated on myeloma cells. Schmidts and colleagues have generated monomeric and trimeric APRIL CAR T-cells, of which the trimeric form
(TriAPRIL-CAR) displayed superior binding to soluble BCMA and TACI and lead to tumour eradication in a murine MM model.\(^9\)

**NK cells.** NK activity is tightly regulated by the overall balance between numerous activating and inhibitory stimuli. KIR-ligand mismatch, indicating nonself, is associated with reduced relapse rate following T-cell depleted alloSCT.\(^9\) An IgG monoclonal antibody directed against three different KIRs (IPH2101) augments NK-mediated lysis of HLA-C-expressing tumour cells *in vitro*,\(^9\) but failed to show clinical benefit in a phase II trial in smouldering myeloma.\(^9\) A recombinant version, lirilumab is presently being tested in combination with elotuzumab (NCT02279394).

Daratumumab relies partly upon NK cells for ADCC, and efficacy is improved by the addition of IMiDs, which upregulate NK activities.\(^4\) However, due to CD38 expression on NK cells, daratumumab significantly depletes NK cells during treatment and for up to 6 months after.\(^9\) Several groups are working on NK cell adoptive transfer to enhance the activity of daratumumab, using approaches to mitigate fratricide such as CD38-deletion, use of low CD38 expressing NK cells or pretreatment of NK cells with Fab fragments to block CD38.\(^9\)\(^,\)\(^8\)\(^,\)\(^9\)

The anti-SLAMF7 monoclonal antibody elotuzumab induces ADCC and also activates NK cells *via* an indirect mechanism dependent on the SLAMF7-associated adaptator protein, EAT-2. Elotuzumab binding to the NK cell SLAMF7 engages EAT-2, activating the MAPK/Erk pathway. As myeloma cells lack EAT-2, elotuzumab-binding does not stimulate the proliferation of MM cells. Again, elotuzumab showed improved clinical benefit when administered with lenalidomide,\(^4\) possibly due to further upregulation of NK activity.

Use of NK cells to stimulate a graft *versus* MM effect *via* KIR-mismatch is also being tested. A phase I study in RRMM used multiple NK cell infusions with lenalidomide or bortezomib-based regimens without significant toxicity. Disease stabilized in four out of five patients, with one response maintained after 12 months.\(^5\) Another group used cord-derived NK cells with lenalidomide and ASCT in 33 patients, producing 83% CR or VGPR at 3 months, with no toxicities reported.\(^5\)

**CAR NK cells** offer an additional possible avenue. The combination of daratumumab with CD38-negative NK cells engineered with the CS1 CAR (SLAMF7) is under investigation, in order to target two myeloma-specific epitopes while avoiding daratumumab-induced NK destruction.\(^1\) A CD38 CAR NK cell line is currently being explored, using an affinity optimized scFv, similar to that reported by Drent and colleagues\(^9\) to facilitate differentiation between CD38-positive NK cells and myeloma cells respectively. *In vitro* results, presented at ASH 2018, have shown high cytotoxicity against MM cells, with *in vivo* results awaited.\(^1\) Initial murine model data regarding an NKG2D-CAR NK cell line have also recently been presented, with further work ongoing.\(^1\)

**Vaccines**

Vaccines are designed to elicit production of tumour-directed T-lymphocytes by the host immune system. The greatest success has been seen after allo- or ASCT, when disease burden is low, and lymphoid reconstitution is occurring with low Treg levels and expansion of CD8* cells.\(^1\) Vaccines can be based on specific, or multiple tumour peptides, whole cells, or incorporating DCs as potent APCs. DCs loaded with/fused to tumour antigens may bypass the DC functional defects seen in myeloma and have provided the most promising results to date. For example, a DC–tumour cell fusion vaccine in RRMM produced a significant rise in myeloma-specific T-cells and disease stabilization for at least 2 months in 70%, with serial vaccination shown to deepen responses post-ASCT.\(^6\) Hypersialylation is a feature of MM\(^1\) which impacts DC function. Sialyltransferase inhibition to enhance DC response may provide a possible means to improve responses to vaccination;\(^3\) however, given the profound impact of myeloma on the immune system, whether this approach will prove clinically useful remains uncertain.

**Conclusion**

Our understanding of the mechanisms that underpin immune evasion by MM cells has increased significantly in recent years, and the development of novel agents that disrupt and target these mechanisms represents a paradigm shift in how we approach the treatment of myeloma.
A wealth of new treatments exists, although in most cases their use is currently limited to the relapsed refractory setting, with many still in clinical trials. Given the worsening immune dysfunction that occurs with disease progression, it is likely that the greatest benefit will be seen with earlier treatment. This may be particularly relevant for patients with high-risk genetic features, those with a suboptimal response to front-line therapy, early relapse within 1 year or those who remain MRD-positive despite intensive therapies, for whom improved treatment options are desperately needed. The optimal sequence of available therapies is also unknown, and how best to manage patients who are refractory to or relapse after front-line therapy involving immunomodulatory agents has recently been highlighted as an area of unmet clinical need.

The most promising results to date have been obtained with CAR T-cell therapies. However, these treatments are associated with significant challenges including treatment delays, potential for severe toxicity, manufacturing issues, logistics required to administer such therapies, and the significant associated costs. These challenges may ultimately limit widespread application of CAR T-cell therapies, therefore interest in the development of ‘off-the-shelf’ alternatives with increased tolerability is growing.

Ultimately, we hope that more effective primary therapy may produce long-lasting, durable remissions, or possibly even cure in a significant fraction of patients.

Author contributions
DS performed the literature review and wrote the manuscript. KL designed Figure 1. MG designed Figures 2 and 3. MOD conceived the review and critically reviewed the manuscript.

Conflict of interest statement
MOD is a Founder and Director of Onkimmune and has received research support from Janssen, Celgene and Bristol Myers Squibb.

Funding
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

ORCID iD
Michael O’Dwyer https://orcid.org/0000-0002-6173-7140

References
1. Rajkumar SV and Kumar S. Multiple myeloma: diagnosis and treatment. Mayo Clin Proc 2016; 91: 101–119.
2. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111: 2516–2120.
3. Donato ML, Siegel DS, Vesole DH, et al. The graft-versus-myeloma effect: chronic graft-versus-host disease but not acute graft-versus-host disease prolongs survival in patients with multiple myeloma receiving allogeneic transplantation. Biol Blood Marrow Transplant 2014; 20: 1211–1216.
4. Lokhorst HM, Schattenberg A, Cornelissen JJ, et al. Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood 1997; 90: 4206–4211.
5. Dosani T, Carlsten M, Maric I, et al. The cellular immune system in myeloma genesis: NK cells and T cells in the development of MM and their uses in immunotherapies. Blood Cancer J 2015; 5: e321.
6. Noonan K, Marchionni L, Anderson J, et al. A novel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myeloma. Blood 2010; 116: 3554–3563.
7. Michalek J, Ocadiikova D, Matejkova E, et al. Individual myeloma-specific T-cell clones eliminate tumour cells and correlate with clinical outcomes in patients with multiple myeloma. Br J Haematol 2010; 148: 859–867.
8. Dhodapkar MV, Krasovsky J, Osman K, et al. Vigorous premalignancy-specific effector T cell response in the bone marrow of patients with monoclonal gammopathy. J Exp Med 2003; 198: 1753–1757.
9. Spisek R, Kukreja A, Chen LC, et al. Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy. J Exp Med 2007; 204: 831–840.
10. Brown RD, Pope B, Yuen E, et al. The expression of T cell related costimulatory molecules in multiple myeloma. Leuk Lymphoma 1998; 31: 379–384.
11. Park JJ, Omiya R, Matsumura Y, et al. B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance. Blood 2010; 116: 1291–1298.
myeloma. Front Immunol 2017; 8: 1444.

17. Niu C, Jin H, Li M, et al. Immunosuppressive effects of multiple myeloma are overcome by PD-L1 blockade. Biol Blood Marrow Transplant 2011; 17: 1133–1145.

18. Feyler S, Scott GB, Parrish C, et al. Tumour cell generation of inducible regulatory T-cells in multiple myeloma is contact-dependent and antigen-presenting cell-independent. PLoS One 2012; 7: e35981.

19. Hoechst B, Voigtlaender T, Ormandy L, et al. Low-dose bortezomib increases the expression of NKG2D and enhances induced NK and CD8+ T cell immunity against multiple myeloma. Blood 2018; blood-2018-01-825265.

20. Li H, Han Y, Guo Q, et al. Generation of antitumor invariant natural killer T cell lines in multiple myeloma and promotion of their functions via lenalidomide: a strategy for immunotherapy. Clin Cancer Res 2008; 14: 6955–6962.

21. Groh V, Wu J, Yee C, et al. Restoring natural killer cell immunity against multiple myeloma in the era of new drugs. Front Immunol 2017; 8: 1444.

22. Lagana A, Ruan DF, Melnekoff D, et al. Increased HLA-E expression correlates with early relapse in multiple myeloma. Blood 2018; 132(Suppl. 1): 59.

23. Jinushi M, Vanneman M, Munshi NC, et al. MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma. Proc Natl Acad Sci USA 2008; 105: 1285–1290.

24. Carbone E, Neri P, Mesuraca M, et al. HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells. Blood 2005; 105: 251–258.

25. Frohn C, Hoppmann M, Schlenke P, et al. Anti-multiple myeloma activity of natural killer lymphocytes. Br J Haematol 2002; 119: 660–664.

26. Daly J, Duggan T, Hu J, et al. Targeting Siglec-7: a novel immunotherapeutic approach to potentiate the cytotoxic functions of natural killer cells against multiple myeloma. Blood 2017; 130(Suppl. 1): 1799.

27. El-Sherbiny YM, Meade JL, Holmes TD, et al. The requirement for DNAM-1, NKG2D, and Nkp46 in the natural killer cell-mediated killing of myeloma cells. Cancer Res 2007; 67: 8444–8449.

28. Beldi-Ferchiou A, Lambert M, Dogniaux S, et al. PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma. Oncotarget 2016; 7: 72961–72977.

29. Ratta M, Fagnoni F, Curti A, et al. Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. Blood 2002; 100: 230–237.

30. Hwang W, Jung K, Jeon Y, et al. Knockdown of the interleukin-6 receptor alpha chain of dendritic cell vaccines enhances the therapeutic potential against IL-6 producing tumors. Vaccine 2010; 29: 34–44.

31. Bull C, Collado-Camps E, Kers-Rebel ED, et al. Metabolic sialic acid blockade lowers the activation threshold of moDCs for TLR stimulation. Immunol Cell Biol 2017; 95: 408–415.

32. Mantovani A, Sozzani S, Locati M, et al. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002; 23: 549–555.

33. Airoldi I, Cocco C, Giuliani N, et al. Constitutive expression of IL-12R beta 2 on human multiple myeloma cells delineates a novel therapeutic target. Blood 2008; 112: 750–759.

34. Neri P, Maity R, Tagoug I, et al. Single cell resolution profiling defines the innate and adaptive immune repertoires modulated by daratumumab and IMiDs treatment in multiple myeloma (MM). Blood 2017; 130 (Suppl. 1): 123.
35. Serafini P, Borrello I and Bronte V. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol 2006; 16: 53–65.

36. Serafini P, Meckel K, Kelso M, et al. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med 2006; 203: 2691–2702.

37. Shapiro-Shelef M and Calame K. Regulation of plasma-cell development. Nat Rev Immunol 2005; 5: 230–242.

38. Lauta VM. A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications. Cancer 2003; 97: 2440–2452.

39. Badros A, Hyjek E, Ma N, et al. Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma. Blood 2017; 130: 1189–1197.

40. Saad Zafar Usmani FS, Albert Oriol R, Lionel K, et al. A phase 3 randomized study of pembrolizumab (pembro) plus lenalidomide (len) and dexamethasone (Dex) for newly diagnosed and treatment-naive multiple myeloma (MM): KEYNOTE-183. J Clin Oncol 2018; 36: Suppl. abstr 8021.

41. Maria-Victoria Mateos HB, Fredrik S and Albert Oriol R. e. A phase 3 randomized study of pembrolizumab (Pembro) plus pomalidomide (Pom) and dexamethasone (Dex) for relapsed/refractory multiple myeloma (RRMM): KEYNOTE-183. J Clin Oncol 2018; 36: Suppl. abstr 8021.

42. Lonial S, Weiss BM, Usmani SZ, et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet 2016; 387: 1551–1560.

43. Dimopoulos MA, Oriol A, Nahi H, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 2016; 375: 1319–1331.

44. Palumbo A, Chanan-Khan A, Weisel K, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med 2016; 375: 754–766.

45. Dimopoulos MA, Lonial S, White D, et al. Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth. Br J Haematol 2017; 178: 896–905.

46. Max ST, Gerhard Z, Michel A, et al. Treatment with AMG 420, an anti-B-cell maturation antigen (BCMA) bispecific T-cell engager (BiTE®) antibody construct, induces minimal residual disease (MRD) negative complete responses in relapsed and/or refractory (R/R) multiple myeloma (MM) patients: results of a first-in-human (FIH) phase I dose escalation study. ASH 2018.

47. Trudel S, Lendvai N, Popat R, et al. Deep and durable responses in patients (Pts) with relapsed/refractory multiple myeloma (MM) treated with monotherapy GSK2857916, an antibody drug conjugate against b-cell maturation antigen (BCMA): preliminary results from part 2 of study BMA117159. Blood 2017; 130(Suppl. 1): 741.

48. Trudel S, Lendvai N, Popat R, et al. Antibody-drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study. Blood Cancer J 2019; 9: 37.

49. Noonan KA, Huff CA, Davis J, et al. Adoptive transfer of activated marrow-infiltrating lymphocytes induces measurable antitumor immunity in the bone marrow in multiple myeloma. Sci Transl Med 2015; 7: 288ra78.

50. Rapoport AP, Stadtmauer EA, Binder-Scholl GK, et al. NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nat Med 2015; 21: 914–921.

51. Garfall AL, Stadtmauer EA, Maus MV, et al. Pilot Study of anti-CD19 chimeric antigen receptor T Cells (CTL019) in conjunction with salvage autologous stem cell transplantation for advanced multiple myeloma. Blood 2016; 128: 974.

52. Xiaolan Shi LY, Jingjing S, Su Q, et al. Tandem autologous transplantation and combined infusion of CD19 and BCMA-specific chimeric antigen receptor T cells for high risk MM: initial safety and efficacy report from a clinical pilot study. ASH 2018.

53. Ali SA, Shi V, Marie I, et al. T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood 2016; 128: 1688–1700.
55. Nina SM, Melissa A, David SS, et al. Initial results from a phase I clinical study of bb21217, a next-generation anti BCMA CAR T therapy clinically relevant abstract. ASCO 2018.

56. Fan F, Zhao W, Liu J, et al. Durable remissions with BCMA-specific chimeric antigen receptor (CAR)-modified T cells in patients with refractory/refractory multiple myeloma. J Clin Oncol 2017; 35 (18_Suppl): LBA3001–LBA.

57. Zhao WH, Liu J, Wang BY, et al. A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma. J Hematol Oncol 2018; 11: 141.

58. Leivas A, Perez-Martinez A, Blanchard MJ, et al. Novel treatment strategy with autologous activated and expanded natural killer cells plus anti-myeloma drugs for multiple myeloma. Oncoimmunology 2016; 5: e1250051.

59. Nina Shah RM, Li L, Jessica M, et al. Phase II study of ex vivo expanded cord blood natural killer cells for multiple myeloma. J Clin Oncol 2018; 36: Suppl. abstr 8006.

60. Rosenblatt J, Avivi I, Vasir B, et al. Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients. Clin Cancer Res 2013; 19: 3640–3648.

61. Reddy N, Hernandez-llilzaliturri FJ, Deeb G, et al. Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. Br J Haematol 2008; 140: 36–45.

62. Henry JY, Labarthe MC, Meyer B, et al. Enhanced cross-priming of naïve CD8+ T cells by dendritic cells treated by the IMiDs(R) immunomodulatory compounds lenalidomide and pomalidomide. Immunology 2013; 139: 377–385.

63. Galustian C, Meyer B, Labarthe MC, et al. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother 2009; 58: 1033–1045.

64. Kronke J, Udeshi ND, Narla A, et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science 2014; 343: 301–305.

65. Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001; 98: 210–216.

66. Wang L, Wang H, Chen H, et al. Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma. Oncotarget 2015; 6: 41228–41236.

67. Suen H, Brown R, Yang S, et al. The failure of immune checkpoint blockade in multiple myeloma with PD-1 inhibitors in a phase 1 study. Leukemia 2015; 29: 1621–1622.

68. Luptakova K, Rosenblatt J, Glotzbecker B, et al. Lenalidomide enhances anti-myeloma cellular immunity. Cancer Immunol Immunother 2013; 62: 39–49.

69. Rigalou A, Ryan A, Natoni A, et al. Potentiation of anti-myeloma activity of daratumumab with combination of cyclophosphamide, lenalidomide or bortezomib via a tumor secretory response that greatly augments macrophage-induced ADCP. Blood 2016; 128: 2101.

70. Naicker S, Rigalou A, McEllistrim C, et al. Patient data supports the rationale of low dose cyclophosphamide to potentiate the anti-myeloma activity of daratumumab through augmentation of macrophage-induced ADCP. Blood 2017; 130(Suppl. 1): 121.

71. Thierry Facon SKK, Torben P, Robert ZO, et al. Phase 3 randomized study of daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (D-Rd) in patients with newly diagnosed multiple myeloma (NDMM) ineligible for transplant (MAIA). ASCO 2018.

72. Fan G, Wang Z, Hao M, et al. Bispecific antibodies and their applications. J Hematol Oncol 2015; 8: 130.

73. Ghosh N and Matsui W. Cancer stem cells in multiple myeloma. Cancer Lett 2009; 277: 1–7.

74. Matsui W, Wang Q, Barber JP, et al. Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res 2008; 68: 190–197.

75. Seckinger A, Delgado JA, Moser S, et al. Target expression, generation, preclinical activity, and pharmacokinetics of the BCMA-T cell bispecific
antibody EM801 for multiple myeloma treatment. Cancer Cell 2017; 31: 396–410.

76. Hipp S, Tai YT, Blanset D, et al. A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo. Leukemia 2017; 31: 2278.

77. Li J, Stagg NJ, Johnston J, et al. Membrane-proximal epitope facilitates efficient T cell synapse formation by anti-FcRH5/CD3 and is a requirement for myeloma cell killing. Cancer Cell 2017; 31: 383–395.

78. Shih-Feng CM, Liang L, Liuje X, et al. Anti-BCMA BiTE® AMG 701 potently induces specific T cell lysis of human multiple myeloma (MM) cells and immunomodulation in the bone marrow microenvironment. ASH 2018.

79. Gantke T, Reusch U, Kellner C, et al. AFM26 - Targeting B cell maturation antigen (BCMA) for NK cell-mediated immunotherapy of multiple myeloma. Blood 2017; 130 (Suppl. 1): 3082.

80. Thorsten RP, Uwe R, Susanne W, et al. Preclinical characterization of AFM26, a novel B cell maturation antigen (BCMA)-directed tetravalent bispecific antibody for high affinity retargeting of NK cells against myeloma. ASH 2018.

81. Gantke T, Weichel M, Herbrecht C, et al. Trispecific antibodies for CD16A-directed NK cell engagement and dual-targeting of tumor cells. Protein Eng Des Sel 2017; 30: 673–684.

82. Cohen AD, Popat R, Trudel S, et al. First in human study with GSK2857916, an antibody drug conjugated to microtubule-disrupting agent directed against B-cell maturation antigen (BCMA) in patients with relapsed/refractory multiple myeloma (MM): results from study BMA117159 part 1 dose escalation. Blood 2016; 128: 1148.

83. Ghiringhelli F, Larmonier N, Schmitt E, et al. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol 2004; 34: 336–344.

84. Rapoport AP, Aqui NA, Stadtmauer EA, et al. Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma. Blood 2011; 117: 788–797.

85. Rapoport AP, Aqui NA, Stadtmauer EA, et al. Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3/Poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cells. Clin Cancer Res 2014; 20: 1355–1365.

86. Qazilbash MH, Stadtmauer EA, Baladandayuthapani V, et al. Randomized phase II trial of combination idiotype vaccine and anti-CD3/anti-CD28 costimulated autologous T cells in patients with multiple myeloma post-autotransplantation. Blood 2016; 128: 4548.

87. Mikkilineni L and Kochenderfer JN. Chimeric antigen receptor T-cell therapies for multiple myeloma. Blood 2017; 130: 2594–2602.

88. Brudno JN and Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood 2016; 127: 3321–3330.

89. Shi X, Yan L, Shang J, et al. Tandem autologous transplantation and combined infusion of CD19 and BCMA-specific chimeric antigen receptor T cells for high risk mm: initial safety and efficacy report from a clinical pilot study. Blood 2018; 132(Suppl. 1): 1009.

90. Eric LSM, Kimberly H, Mette S, et al. CAR T cell therapy targeting g protein-coupled receptor class C group 5 member D (GPRC5D), a novel target for the immunotherapy of multiple myeloma. ASH 2018.

91. Drent E, Themeli M, Poels R, et al. A rational strategy for reducing on-target off-tumor effects of CD38-chimeric antigen receptors by affinity optimization. Mol Ther 2017; 25: 1946–1958.

92. Carpenter RO, Evbuomwan MO, Pittaluga S, et al. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. ASH 2018.

93. Andrea SM, Maria O, Allison OT, et al. Engineering an optimized trimeric APRIL-based CAR to broaden targetability of multiple myeloma clinically relevant abstract. ASH 2018.

94. Velardi A, Ruggeri L, Alessandro M, et al. NK cells: a lesson from mismatched hematopoietic transplantation. Trends Immunol 2002; 23: 438–444.

95. Romagne F, Andre P, Spec P, et al. Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. Blood 2009; 114: 2667–2677.

96. Korde N, Carlsten M, Lee MJ, et al. A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma. Haematologica 2014; 99: e81–e83.
97. Casneuf T, Xu XS, Adams HC, et al. Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma. *Blood Adv* 2017; 1: 2105–2114.

98. Nijhof IS, Lammerts van Bueren JJ, van Kessel B, et al. Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide. *Haematologica* 2015; 100: 263–268.

99. Karrune Woan M, Ryan B, Frank C, et al. CD38-deficient, CD16-engineered NK cells exhibit enhanced antibody-dependent cellular cytotoxicity without NK cell fratricide to augment anti-myeloma immunity in combination with daratumumab. *ASH* 2018.

100. Wang Y, Zhang Y, Bnson D, et al. Abstract 4617: daratumumab combined with CD38(-) natural killer cells armed with a CS1 chimeric antigen receptor for the treatment of relapsed multiple myeloma. *Cancer Res* 2017; 77(13 Suppl. 13): 4617.

101. Arwen Stikvoort P, Subhashis S, Renée P, et al. CD38 specific chimeric antigen receptor KHYG-1 natural killer cells: a potential “off the shelf” therapy for multiple myeloma. *ASH* 2018.

102. Alejandra LP, Paula R, Rebeca M, et al. NKG2D-CAR transduced primary natural killer cells efficiently target multiple myeloma cells. *ASH* 2018.

103. Liegel J, Avigan D and Rosenblatt J. Cellular immunotherapy as a therapeutic approach in multiple myeloma. *Expert Rev Hematol* 2018; 11: 525–536.

104. Glavey SV, Manier S, Natoni A, et al. The sialyltransferase ST3GAL6 influences homing and survival in multiple myeloma. *Blood* 2014; 124: 1765–1776.

105. Moreau P, Zamagni E and Mateos M-V. Treatment of patients with multiple myeloma progressing on frontline therapy with lenalidomide. *Blood Cancer J* 2019; 9: 38.